DK1531819T3 - Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen - Google Patents

Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Info

Publication number: DK1531819T3
Authority: DK; Denmark
Prior art keywords: kinase inhibitors; pain management; ikappab kinase; ikappab; pain
Prior art date: 2002-08-17

Application number

DK03753349T

Other languages

Danish (da)

English (en)

Inventor

Martin Michaelis

Olaf Ritzeler

Gerhard Jaehne

Karl Rudolphi

Gerd Geisslinger

Hans-Georg Schaible

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-17

Filing date

2003-08-05

Publication date

2009-04-20

2003-08-05 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2009-04-20 Application granted granted Critical

2009-04-20 Publication of DK1531819T3 publication Critical patent/DK1531819T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Paper (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK03753349T 2002-08-17 2003-08-05 Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen DK1531819T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10237723A DE10237723A1 (de)	2002-08-17	2002-08-17	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (fr)	2002-08-17	2003-08-05	UTILISATION D'INHIBITEURS DE L'IλB KINASE DANS LE TRAITEMENT DE LA DOULEUR

Publications (1)

Publication Number	Publication Date
DK1531819T3 true DK1531819T3 (da)	2009-04-20

Family

ID=31968975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03753349T DK1531819T3 (da)	2002-08-17	2003-08-05	Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Country Status (34)

Country	Link
EP (1)	EP1531819B1 (fr)
JP (1)	JP4504811B2 (fr)
KR (2)	KR101119845B1 (fr)
CN (1)	CN100398107C (fr)
AR (1)	AR043045A1 (fr)
AT (1)	ATE418336T1 (fr)
AU (1)	AU2003271555B2 (fr)
BR (1)	BR0313555A (fr)
CA (1)	CA2495455C (fr)
CO (1)	CO5690585A2 (fr)
CR (1)	CR7716A (fr)
CY (1)	CY1108874T1 (fr)
DE (2)	DE10237723A1 (fr)
DK (1)	DK1531819T3 (fr)
EC (1)	ECSP055609A (fr)
ES (1)	ES2320118T3 (fr)
HK (1)	HK1079426A1 (fr)
HR (1)	HRP20050041B1 (fr)
IL (1)	IL166780A (fr)
MA (1)	MA27334A1 (fr)
MX (1)	MXPA05001218A (fr)
MY (1)	MY138059A (fr)
NO (1)	NO334309B1 (fr)
OA (1)	OA12907A (fr)
PL (1)	PL212356B1 (fr)
PT (1)	PT1531819E (fr)
RS (1)	RS51878B (fr)
RU (1)	RU2320338C2 (fr)
SI (1)	SI1531819T1 (fr)
TN (1)	TNSN05044A1 (fr)
TW (1)	TWI325782B (fr)
UA (1)	UA80837C2 (fr)
WO (1)	WO2004022057A1 (fr)
ZA (1)	ZA200500323B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en)	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en)	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en)	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en)	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en)	2003-03-07	2004-09-23	The Trustees Of Columbia University, In The City Of New York	Type 1 ryanodine receptor-based methods
US8710045B2 (en)	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
MX2007000481A (es)	2004-07-14	2007-03-29	Ptc Therapeutics Inc	Metodos para tratar hepatitis c.
US7868037B2 (en)	2004-07-14	2011-01-11	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7772271B2 (en)	2004-07-14	2010-08-10	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
JP2008507518A (ja)	2004-07-22	2008-03-13	ピーティーシーセラピューティクス，インコーポレーテッド	Ｃ型肝炎を治療するためのチエノピリジン
DE102005025225A1 (de) *	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en)	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5790440B2 (ja) *	2010-12-01	2015-10-07	住友化学株式会社	ピリミジン化合物およびその有害生物防除用途
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120054A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (fr)	2011-03-08	2015-02-18	Sanofi	Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2532755A1 (fr) *	2011-06-10	2012-12-12	Sanofi-Aventis	Procédés et utilisations basés sur l'expression de Slfn2 et liés à l'identification et au profilage de composés pour une utilisation dans le traitement ou la prévention de la douleur
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
PT2787998T (pt)	2011-12-06	2017-01-03	Sanofi Sa	Formas cristalinas de [(s)-1-carbamoil-2-(fenil-pirimidin- 2-il-amino)-etil]-amida do ácido 2-(2-metilamino-pirimidin- 4-il)-1h-indole-5-carboxílico
EP3184095A1 (fr)	2013-05-23	2017-06-28	IP Gesellschaft für Management mbH	Unitées d'administration comprennante une polymorphe 1 de 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
RU2687094C2 (ru) *	2014-07-03	2019-05-07	Санофи	[(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амид 2-(2-метиламинопиримидин-4-ил)-1h-индол-5-карбоновой кислоты для применения в лечении связанной с остеоартритом боли
EP3823963A2 (fr)	2018-07-16	2021-05-26	Novartis AG	Procédé chimique pour la préparation de dérivés de phénylpipéridinyl indole

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04813B1 (et) *	1999-06-23	2007-04-16	Aventis Pharma Deutschland Gmbh	Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

2002
- 2002-08-17 DE DE10237723A patent/DE10237723A1/de not_active Withdrawn
2003
- 2003-05-08 UA UAA200502388A patent/UA80837C2/uk unknown
- 2003-08-05 DK DK03753349T patent/DK1531819T3/da active
- 2003-08-05 ES ES03753349T patent/ES2320118T3/es not_active Expired - Lifetime
- 2003-08-05 SI SI200331531T patent/SI1531819T1/sl unknown
- 2003-08-05 RS YU20050070A patent/RS51878B/sr unknown
- 2003-08-05 DE DE50310980T patent/DE50310980D1/de not_active Expired - Lifetime
- 2003-08-05 AU AU2003271555A patent/AU2003271555B2/en not_active Ceased
- 2003-08-05 MX MXPA05001218A patent/MXPA05001218A/es active IP Right Grant
- 2003-08-05 EP EP03753349A patent/EP1531819B1/fr not_active Expired - Lifetime
- 2003-08-05 CN CNB038195429A patent/CN100398107C/zh not_active Expired - Fee Related
- 2003-08-05 OA OA1200500046A patent/OA12907A/en unknown
- 2003-08-05 JP JP2004533318A patent/JP4504811B2/ja not_active Expired - Fee Related
- 2003-08-05 WO PCT/EP2003/008628 patent/WO2004022057A1/fr active Application Filing
- 2003-08-05 KR KR1020057002712A patent/KR101119845B1/ko not_active IP Right Cessation
- 2003-08-05 KR KR1020117028345A patent/KR20110135428A/ko not_active Application Discontinuation
- 2003-08-05 PL PL373568A patent/PL212356B1/pl unknown
- 2003-08-05 PT PT03753349T patent/PT1531819E/pt unknown
- 2003-08-05 AT AT03753349T patent/ATE418336T1/de active
- 2003-08-05 RU RU2005107419/15A patent/RU2320338C2/ru not_active IP Right Cessation
- 2003-08-05 BR BR0313555-1A patent/BR0313555A/pt not_active Application Discontinuation
- 2003-08-05 CA CA2495455A patent/CA2495455C/fr not_active Expired - Fee Related
- 2003-08-14 TW TW092122310A patent/TWI325782B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102944A patent/AR043045A1/es not_active Application Discontinuation
- 2003-08-15 MY MYPI20033112A patent/MY138059A/en unknown
2005
- 2005-01-13 ZA ZA200500323A patent/ZA200500323B/xx unknown
- 2005-01-14 HR HRP20050041AA patent/HRP20050041B1/hr not_active IP Right Cessation
- 2005-02-09 IL IL166780A patent/IL166780A/en not_active IP Right Cessation
- 2005-02-15 CO CO05013333A patent/CO5690585A2/es not_active Application Discontinuation
- 2005-02-15 MA MA28107A patent/MA27334A1/fr unknown
- 2005-02-16 TN TNP2005000044A patent/TNSN05044A1/en unknown
- 2005-02-17 EC EC2005005609A patent/ECSP055609A/es unknown
- 2005-03-07 CR CR7716A patent/CR7716A/es unknown
- 2005-03-15 NO NO20051339A patent/NO334309B1/no not_active IP Right Cessation
- 2005-12-12 HK HK05111381.9A patent/HK1079426A1/xx not_active IP Right Cessation
2009
- 2009-03-17 CY CY20091100291T patent/CY1108874T1/el unknown

Also Published As

Publication number	Publication date
WO2004022057A1 (fr)	2004-03-18
IL166780A (en)	2011-11-30
KR20110135428A (ko)	2011-12-16
RU2005107419A (ru)	2005-08-10
CN1674899A (zh)	2005-09-28
AU2003271555B2 (en)	2009-03-26
RS51878B (sr)	2012-02-29
CY1108874T1 (el)	2014-07-02
BR0313555A (pt)	2005-07-12
IL166780A0 (en)	2006-01-15
EP1531819A1 (fr)	2005-05-25
JP2005539053A (ja)	2005-12-22
MXPA05001218A (es)	2005-05-16
HK1079426A1 (en)	2006-04-07
SI1531819T1 (sl)	2009-06-30
AR043045A1 (es)	2005-07-13
CR7716A (es)	2008-11-25
ECSP055609A (es)	2005-04-18
CA2495455A1 (fr)	2004-03-18
JP4504811B2 (ja)	2010-07-14
ZA200500323B (en)	2006-02-22
PT1531819E (pt)	2009-02-18
PL212356B1 (pl)	2012-09-28
EP1531819B1 (fr)	2008-12-24
MY138059A (en)	2009-04-30
AU2003271555A1 (en)	2004-03-29
KR20050058339A (ko)	2005-06-16
ATE418336T1 (de)	2009-01-15
TWI325782B (en)	2010-06-11
CN100398107C (zh)	2008-07-02
HRP20050041A2 (hr)	2006-04-30
TW200417370A (en)	2004-09-16
RU2320338C2 (ru)	2008-03-27
HRP20050041B1 (hr)	2013-07-31
DE50310980D1 (de)	2009-02-05
CO5690585A2 (es)	2006-10-31
OA12907A (en)	2006-10-13
CA2495455C (fr)	2011-01-11
RS20050070A (en)	2007-06-04
TNSN05044A1 (en)	2007-05-14
NO20051339L (no)	2005-05-03
ES2320118T3 (es)	2009-05-19
PL373568A1 (en)	2005-09-05
UA80837C2 (uk)	2007-11-12
MA27334A1 (fr)	2005-05-02
KR101119845B1 (ko)	2012-02-28
DE10237723A1 (de)	2004-07-08
NO334309B1 (no)	2014-02-03

Publication	Publication Date	Title
DK1531819T3 (da)	2009-04-20	Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen
DK1534290T3 (da)	2012-04-10	Hidtil ukendte kinasehæmmere
IS7599A (is)	2004-12-15	Heterósýklískir kínasatálmar
DK1532138T3 (da)	2009-03-23	Inhibitorer af tyrosinkinaser
IS7700A (is)	2005-02-17	Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
HK1078779A1 (en)	2006-03-24	Substituted benzazoles and use thereof as raf kinase inhibitors
DE60313106D1 (de)	2007-05-24	Zugangsverwaltung
EP1507541A4 (fr)	2009-06-03	Inhibiteurs et procedes d'utilisation de ceux-ci
IS6968A (is)	2003-09-26	Nýir týrósínkínasa tálmar
ES2867378T8 (es)	2022-02-10	Epinefrina inhalable
DE60208661D1 (de)	2006-04-06	Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE50209166D1 (de)	2007-02-15	Innenkühlbare Schraube
EP1691812A4 (fr)	2010-01-13	Inhibiteurs de gtpase et procedes d'utilisation correspondants
DK1675852T3 (da)	2009-05-25	Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
SE0400663L (sv)	2005-09-17	Hantering av osäkerhet i ledningssystem
NO20044104L (no)	2004-12-01	Ikke-nukleoside reverstranskriptase-inhibitorer
EE200300491A (et)	2004-02-16	6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
EP1688126A4 (fr)	2009-11-04	Inhibiteurs de parakeratose et composition externe cutanee
DE602004022935D1 (de)	2009-10-15	Verbesserungen des stimulationserfolgs-managements
DK1496918T3 (da)	2023-05-15	Anvendelse af natriummetaarsenit til behandling af tumorer
ATE373648T1 (de)	2007-10-15	Nf-kappab-inhibitoren
DE60229669D1 (de)	2008-12-11	X-2 inhibitoren
EP1806132A4 (fr)	2008-02-20	Inhibiteur de phosphorylation de stat3 et inhibiteur d'expression de notch1
SE0203540D0 (sv)	2002-11-28	Use of an inhibilor or antagonist against lissue factor
SE0200545D0 (sv)	2002-02-22	Use of an inhibitor or antagonist against tissue factor